Stimulant Use Disorder: Behavioral Treatment and Referral Options

When a person using cocaine or methamphetamine asks for help, the next step is not always straightforward. Cravings may coexist with exhaustion, disrupted sleep, anxiety, or difficulty keeping appointments. A referring clinician may need to address immediate safety while finding treatment the person can realistically attend.

Stimulant use disorder can be treated with behavioral interventions and individualized support. Contingency management is a leading evidence-based approach. Medication decisions, co-occurring conditions, and level of care require clinical assessment; a diagnosis alone does not establish that someone needs intensive outpatient treatment.

This guide focuses on the provider's decision path: what to assess, which treatment questions to ask, and how to make a coordinated referral without treating difficulty engaging as a personal failure. It is educational information, not individualized medical advice.

Assess the pattern and its impact, not just the substance

Stimulant use disorder involves a pattern of use associated with clinically significant impairment or distress. Assessment considers such features as difficulty controlling use, craving, continued use despite harm, and effects on daily functioning. The presence of one symptom, or stimulant exposure alone, is not enough to diagnose the disorder.

Cocaine and methamphetamine differ in their effects and duration, and individual experiences vary. The National Institute on Drug Abuse's methamphetamine overview describes potential effects on sleep, mood, thinking, cardiovascular health, and behavior. Do not assume a person's presentation from the drug name alone.

Ask about the timing and amount of use, routes of administration, periods without use, other substances, prescribed medications, and previous treatment experiences. Explore sleep, nutrition, housing, work demands, relationships, and what the person hopes will change. These practical details help establish an achievable plan rather than a referral based only on a diagnostic label.

Symptoms such as anxiety, poor concentration, low mood, or suspiciousness need careful evaluation. Their relationship to intoxication, withdrawal, an independent mental health condition, or another medical concern may take time to clarify. Avoid assuming that every symptom will disappear with abstinence or that every symptom represents a separate disorder.

Distinguish an outpatient referral from an urgent evaluation

Before discussing routine program placement, assess for immediate medical and psychiatric risk. Chest pain, seizure, severe overheating, marked confusion, dangerous agitation, or an immediate risk of self-harm requires urgent evaluation. New or worsening psychotic symptoms also warrant prompt assessment, with emergency care when safety is compromised. An admissions call is not a substitute for emergency care.

Stimulant withdrawal can involve fatigue, sleep changes, depressed mood, reduced ability to experience pleasure, and craving. These concerns should not be minimized because stimulant withdrawal differs from alcohol or benzodiazepine withdrawal. The ASAM/AAAP stimulant use disorder guideline addresses monitoring for psychiatric complications and matching care to the person's condition.

Ask about opioid exposure and other substance use rather than assuming that a stimulant is the only substance involved. NIDA notes that methamphetamine-related overdose can involve opioids, including fentanyl. Overdose education and access to naloxone may be relevant when opioid exposure is possible. Naloxone reverses opioid overdose; it does not reverse stimulant toxicity. Refer for emergency help when overdose or serious toxicity is suspected.

Behavioral treatment is an active treatment plan

The absence of a medication specifically approved for a condition should never be presented as the absence of treatment. The ASAM/AAAP guideline identifies contingency management as a primary component of stimulant use disorder treatment and discusses other behavioral approaches that can be used alongside it. NIDA similarly highlights contingency management in its discussion of methamphetamine treatment.

Contingency management

Contingency management uses structured, tangible incentives to reinforce agreed treatment goals, such as attendance or objectively measured reductions in substance use. It is a defined clinical intervention, not an informal reward offered whenever a clinician feels someone is doing well. Programs need appropriate procedures, training, funding, and compliance with applicable requirements.

For a referral, ask whether the receiving program actually provides contingency management and what its implementation involves. Do not assume that every substance use program offers it. If a program does not, discuss whether another service or coordinated treatment arrangement can provide access. This article does not establish that Waterview offers contingency management.

CBT and community reinforcement

Cognitive behavioral therapy, or CBT, can help people recognize triggers, examine thoughts linked to use, practice coping strategies, and plan responses to cravings. Community reinforcement focuses on building rewarding activities and relationships that do not revolve around substance use. Motivational approaches can support a conversation about change without insisting that the person arrive fully confident or certain.

Ask how the proposed treatment addresses the person's particular pattern. A plan may need to consider a work schedule associated with use, social contacts who use substances, isolation, or distress that precedes cravings. Skills work should connect with these realities rather than remain a list of strategies the person cannot use in daily life.

Keep medication discussions accurate and individualized

The ASAM/AAAP guideline describes a treatment landscape without an FDA-approved medication specifically for stimulant use disorder and discusses selected off-label medication options. Off-label prescribing means using an approved medication for an indication outside its FDA labeling. It is not equivalent to having an FDA-approved treatment for stimulant use disorder.

A qualified prescriber may consider medication based on the substance involved, co-occurring conditions, potential benefits, risks, and monitoring needs. This is different from advising every person with stimulant use disorder to take the same medicine. Medication names, combinations, and dosing are outside the scope of this referral guide.

Care for depression, anxiety, ADHD, or other conditions should also be individualized. Avoid blanket statements that medications are never helpful, and do not recommend starting, stopping, or changing prescriptions without the treating clinician. Because evidence and labeling can change, prescribers should consult current guidance and prescribing information.

Match treatment intensity to current needs

Some people can participate in standard outpatient treatment with suitable supports. Others may need intensive outpatient, partial hospitalization, residential, or inpatient care. The decision depends on medical and psychiatric stability, safety, recovery environment, ability to participate, and the person's preferences—not simply on whether the substance is cocaine or methamphetamine.

An intensive outpatient program can provide more frequent clinical contact and opportunities to practice skills while the person continues living outside a residential setting. It does not provide around-the-clock supervision or replace medically necessary hospital care.

Consider what is happening between appointments. Can the person follow the plan safely? Are transportation, sleep disruption, caregiving, or work hours preventing attendance? Is there adequate support where they live? Would another setting address needs that the proposed outpatient program cannot meet?

A person should not have to demonstrate personal failure to justify a different level of care. Equally, more hours of treatment are not automatically better. The goal is an appropriate match, with reassessment as circumstances change. Waterview's substance use disorder treatment information can support an initial conversation about services and assessment, without establishing eligibility for any particular person.

Make engagement part of the clinical plan

Early recovery may include low energy, irregular sleep, irritability, and difficulty concentrating. These experiences can complicate attendance, but they do not explain every missed visit. Ask what happened and what would make the next appointment more workable instead of labeling the person unmotivated or noncompliant.

Agree on a manageable first step, confirm how the person wants to be contacted, and identify practical barriers before the handoff. With permission, a coordinated introduction may be more useful than providing a phone number alone. Be clear about who will follow up if an assessment is missed and how the person can reconnect.

Co-occurring mental health needs should remain visible throughout this process. Waterview's information on support for co-occurring disorders explains the relevance of considering mental health and substance use together. A referral should clarify how current clinicians and the receiving team will coordinate, within consent and confidentiality requirements.

Family or other support involvement can be helpful when appropriate and authorized. Ask whom the person wants involved, what can be shared, and what boundaries matter. Supporters should not be asked to diagnose withdrawal, monitor medication independently, or replace professional assessment.

Build a referral that answers practical questions

A useful handoff summarizes the reason for referral, current safety concerns, relevant treatment history, present supports, and the specific question the receiving clinician is being asked to address. Share only information needed for care through approved secure channels, with appropriate authorization and attention to substance use record protections.

Before the transition, establish:

• Who will complete the assessment and how the person will access it.

• Which services are available, including whether contingency management is offered.

• Who is responsible for prescribing, follow-up, and communication during the transition.

• What insurance, scheduling, transportation, or accessibility questions remain.

• How changes in safety or treatment needs will trigger reassessment.

Discuss these questions with the person, not only about them. A referral that preserves choice and continuity is more useful than a promise of outcomes or an assumption that admission is assured.

Discuss a coordinated next step with Waterview

For Connecticut clinicians considering structured outpatient support, Waterview Behavioral Health can be contacted to discuss assessment and current program information. Ask about the person's needs, available services, treatment scheduling, and coordination with existing clinicians. Do not assume that a specialized intervention is available without confirming it.

Use Waterview's contact page for a referral-coordination conversation or call 860-421-6829. Send clinical information only through an approved secure process. An information conversation does not guarantee admission, insurance coverage, or a particular treatment outcome.

Frequently asked referral questions

Does prescribed stimulant use automatically mean someone has a use disorder?

No. Taking a prescribed medication as directed is not, by itself, evidence of stimulant use disorder. Concerns about medication use require an individualized assessment rather than assumptions based on the medication's name or drug class.

Can a referral begin if the person is unsure about stopping?

A clinician can discuss goals, risks, and assessment while acknowledging uncertainty. Ask the receiving program about its assessment process, participation requirements, and how it works with ambivalence. Do not assume that all programs have identical entry criteria.

What should the referring clinician do while an assessment is pending?

Clarify responsibility for ongoing care, safety monitoring, prescriptions, and follow-up rather than assuming the receiving program has taken over. Escalate urgent concerns through appropriate emergency or crisis services instead of waiting for a routine appointment.

Clinical source notes: This article draws on the ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder and NIDA's methamphetamine overview. It does not provide diagnosis, prescribing advice, or individualized level-of-care recommendations.